Screener
Tarsus Pharmaceuticals, Inc. TARS Comprehensive Income (Loss), Net of Tax, Attributable to Parent
Comprehensive Income (Loss), Net of Tax, Attributable to Parent at other companies
Other financials
Where this comes from
Reported directly by Tarsus Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ComprehensiveIncomeNetOfTax.
The source filing: Tarsus Pharmaceuticals, Inc.’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 7:25 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001819790-26-000064
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Other income (expense), net | (281) | (145) | (368) | (226) |
| Total other income (expense), net | 4,073 | 1,844 | 5,580 | 3,004 |
| Provision for income taxes | (2,716) | — | (5,068) | — |
| Net loss | $(18,551) | $(20,340) | $(25,518) | $(45,460) |
| Unrealized gain (loss) on marketable securities and cash equivalents | (259) | (46) | (938) | (140) |
| Comprehensive loss | $(18,810) | $(20,386) | $(26,456) | $(45,600) |
| Net loss per share, basic and diluted | $(0.43) | $(0.48) | $(0.59) | $(1.11) |
| Weighted-average shares outstanding, basic and diluted | 43,393,643 | 42,360,452 | 43,176,514 | 40,869,364 |
Item 1. Financial Statements
FAQ
- What is Tarsus Pharmaceuticals, Inc.'s comprehensive income (loss), net of tax, attributable to parent?
- Tarsus Pharmaceuticals, Inc. (TARS) reported comprehensive income (loss), net of tax, attributable to parent of -$18.81M in Q2 2026.
- How has Tarsus Pharmaceuticals, Inc.'s comprehensive income (loss), net of tax, attributable to parent changed year-over-year?
- Tarsus Pharmaceuticals, Inc.'s comprehensive income (loss), net of tax, attributable to parent increased by 7.7% year-over-year, from -$20.39M to -$18.81M.
- What is the long-term trend for Tarsus Pharmaceuticals, Inc.'s comprehensive income (loss), net of tax, attributable to parent?
- Over 4 years (2021 to 2025), Tarsus Pharmaceuticals, Inc.'s comprehensive income (loss), net of tax, attributable to parent has grown at a 47.9% compound annual growth rate (CAGR), from -$13.83M to -$66.22M.
- What does comprehensive income (loss), net of tax, attributable to parent mean?
- This metric represents the total change in equity resulting from both net income and other comprehensive income items, such as unrealized gains or losses on securities. It provides a holistic view of the company's financial performance by including non-owner changes in equity that are typically excluded from the standard net income calculation. This figure is essential for understanding the total impact of all financial activities on the company's net worth.
Ask your AI about Tarsus Pharmaceuticals, Inc.'s comprehensive income (loss), net of tax, attributable to parent.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude